Dr. Rodrigo Martinez Maza is currently principal researcher at the Molecular Neuroprotection Group of the Research Unit of the National Hospital for Paraplegics (SESCAM, Spain) since 2005. He obtained his PhD in Biochemistry and Molecular Biology at the CBM Severo-Ochoa, Autonomous University of Madrid (Spain) (1996-1999) on the molecular characterisation of subtypes of glycine neurotransmitter transporters. He joined at the Dan Lindholm Lab at the Neuroscience Institute at the Biomedicine Center (Uppsala U., Uppsala, Sweden, 2000-2005), as a Marie Curie postdoctoral fellow to search for mechanisms by which anti-apoptotic proteins protect neurons against different apoptotic stimuli. His interest has always been focused on neuroscience, in particular the molecular approach to the study of neurodegenerative diseases. His research has contributed to the understanding of programmed cell death after traumatic spinal cord injury and the development of some new therapeutic strategies for the treatment of spinal cord injury based on modulation of cell death.
Dr. Rodrigo Martinez Maza is currently principal researcher at the Molecular Neuroprotection Group of the Research Unit of the National Hospital for Paraplegics (SESCAM, Spain) since 2005. He obtained his PhD in Biochemistry and Molecular Biology at the CBM Severo-Ochoa, Autonomous University of Madrid (Spain) (1996-1999) on the molecular characterisation of subtypes of glycine neurotransmitter transporters. He joined at the Dan Lindholm Lab at the Neuroscience Institute at the Biomedicine Center (Uppsala U., Uppsala, Sweden, 2000-2005), as a Marie Curie postdoctoral fellow to search for mechanisms by which anti-apoptotic proteins protect neurons against different apoptotic stimuli. His interest has always been focused on neuroscience, in particular the molecular approach to the study of neurodegenerative diseases. His research has contributed to the understanding of programmed cell death after traumatic spinal cord injury and the development of some new therapeutic strategies for the treatment of spinal cord injury based on modulation of cell death.